The Beilhack Lab welcomes Kerstin Sarter Zaiss, PhD. Kerstin graduated from University Erlangen-Nuremberg, Germany, where she completed her thesis work on Galectins at the Institute of Clinical Immunology. After postdoctoral training in Erlangen she moved to the Department of Pathology and Immunology at University of Geneva Medical School, Switzerland. Kerstin is an expert in preclinical mouse models and clinical immunology.
The Beilhack Lab welcomes Zeinab Mokhtari, PhD. Zeinab graduated from the distinguished research group of Prof. Marc Thilo Figge at Friedrich-Schiller-University Jena, Germany. She has a strong background in applied systems biology and is an expert on the quantitative analysis of migrating and interacting immune cells from image data.
Mokhtari et al. (2014). PLoS ONE 9(12): e115158.
Dr. Jorge Amich has been awarded with an MRC Career Development Award of the Medical Research Council, UK.
Stefanie Schwinn was selected from 300 applicants for a “Medical Excellence Scholarship” of the Manfred Lautenschläger-Stiftung, which will support her brain cancer research.
Natarajaswamy Kalleda had been selected for an inner circle poster award at the 4th European Congress of Immunology (ECI 2015), September 6 – 9th, 2015 in Vienna, Austria.
Dr. Ana-Laura Jordán Garrote has received the 2015 Else-Kröner Poster Award for Translational Immunology.
Nobel Laureate Prof. Harald zur Hausen presented his latest research on intestinal cancer. Together with Dr. Susanne Schultz-Hector from the Else Kröner-Fresenius-Stiftung he awarded the diplomas to the Else-Kröner-Fellows of Würzburg’s clinician-scientist training program, the Else-Kröner-Forschungskolleg for Interdisciplinary Translational Medicine. Prof. Jörg Wischhusen, speaker of our Else-Kröner-Forschungskolleg, provided musical highlights on the piano with pieces from Rachmaninoff and Albéniz to close the ceremony.
Picture: Jörg Fuchs, Else-Kröner-Forschungskolleg Würzburg
Leaders in the field of immunotherapy presented their recent scientific and clinical advances at the Else-Kröner-Symposium “Translational Immunology – From Target to Therapy”. The meeting from October 29-30, 2015 provided again an excellent opportunity for young scientists to present and discuss their own research with international experts in the fields of cancer immunotherapy, inflammation, autoimmune and infectious diseases.
Our conference was generously supported by the Else Kröner-Fresenius-Stiftung and took place in the beautiful historical venue of the Juliusspital in Würzburg, where Rudolf Virchow laid important foundations for modern pathology.
In a collaborative project between our team and the group of Prof. Harald Wajant we discovered a mechanism how Fn14 blockade with an ADCC-defective human immunoglobulin G1 antibody reduced acute graft-versus-host disease, a life-threatening complication after allogeneic hematopoietic transplantation, while not impairing immune responses against lymphomas. The publication of Martin Chopra et al. is accompanied by an editorial by David J. MacEwan:
Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A*, Wajant H*. (2015). Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GvHD. Blood 126(4):437-444.
© 2015 by The American Society of Hematology
Profs. Harald Wajant and Andreas Beilhack participated at the 4th BioEntrepreneur Boot Camp under the leadership of BioM Biotech Cluster Development of the Bavarian State Government, a three-day intensive training program for scientists in the start-up phase for a biotech company. Both scientists were coached by a successful biotech entrepreneur, Prof. Uwe Jacob. On the last day of the training program both scientists presented their business plan together with the other projects of twelve participating teams in front of an expert jury at the Show Down Breakfast. The presentation of the business idea for personalized cancer therapy of Beilhack and Wajant was selected for the first prize. The future start-up company will develop a new drug to regulate the immune system in cancer patients.
Picture: © BioM Biotech Cluster Development GmbH